Oxford Biomedica plc, the leading gene and cell therapy group which is manufacturing the AstraZeneca vaccine at its Oxford facility, is to boost production of the vaccine in the second half of the year.
Following successful manufacture of large-scale batches of AstraZeneca’s COVID-19 Vaccine, AstraZeneca has committed to an increase in the number of batches required from Oxford Biomedica in the second half of 2021. As a result of this, Oxford Biomedica Group has doubled its revenue forecasts from in excess of £50 million to in excess of £100 million.
John Dawson, Chief Executive Officer of Oxford Biomedica, said: “Everyone involved with production of the COVID-19 Vaccine can be truly proud of their achievement in manufacturing batches of vaccine from our Oxbox manufacturing facility. We are delighted to be a key supplier of the vaccine and the Group is proud to be part of this world-leading vaccination project that is saving many lives.”